CRISPR Therapeutics (CRSP) stock slips after a strong rally driven by earnings beats and analyst upgrades. Explore future catalysts and investment insights.

In terms of liquidity and interest, the mean open interest for CRISPR Therapeutics options trades today is 628.14 with a total volume of 1,152.00.

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...

The evolution of cell and gene therapy is reshaping drug discovery, providing new hope for rare diseases and cancer through innovative gene editing approaches.

With a market cap of $118.7 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology leader specializing ...

In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals, their decades-long ...

An SCD patient in Bahrain received the gene-editing therapy Casgevy, marking the first time the treatment has been given outside the U.S.

The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.

CRISPR Therapeutics CRSP stock rose more than 25% in the past week, thanks to the encouraging fourth-quarter 2024 results and ...

The reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE) issues positive guidance recommending CASGEVY’s use in the NHS. It means that eligible SCD ...

HRH Prince Salman highlighted the Kingdom’s medical milestone in successfully completing the treatment of the world’s first sickle cell disease patient outside the US with Casgevy (exagamglogene ...

This achievement follows Bahrain’s landmark decision on 2 December 2023 to become the second country globally and the first ...